[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hidradenitis-suppurativa-hs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hidradenitis-suppurativa-hs":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,49,73,99,127,158,184,210,230,257,277,297,319,347,370,397,424,442,466,485,505,530,595,614,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100609391","phase-2-pharmacokinetics-safety-and-efficacy-of-povorcitinib-in-adolescent-participants-with-moderate-to-severe-hidradenitis-suppurativa-100609391",false,"NCT07213973","Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa","A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Aged ≥ 12 to \\\u003C 18 years at the time of informed consent\u002Fassent signing.\n* Body weight ≥ 30 kg at both screening and baseline visits.\n* Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit.\n* Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits.\n* HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits.\n* Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS).\n* Agreement to use contraception.\n* Willing and able to comply with the study protocol and procedures.\n* Further inclusion criteria apply.\n\nExclusion Criteria:\n\n* Presence of \\> 20 draining tunnels (fistulas) at either the screening or baseline visit.\n* Women who are pregnant (or who are considering pregnancy) or breastfeeding.\n* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.\n* Laboratory values outside of the protocol-defined ranges.\n* Further exclusion criteria apply.","ALL","12 Years","17 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.",[28],"Hidradenitis Suppurativa (HS)",[30,31,32,33,34,35],"Hidradenitis Suppurativa","HS","INCB054707","Povorcitinib","Acne inversa","Hidradenitis","RECRUITING","2026-06-29",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":40},"2026-02-02",{"date":44,"type":22},"2028-03-25",{"name":46,"class":47},"Incyte Corporation","INDUSTRY",30,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100581837","phase-3-rollover-study-for-participants-previously-enrolled-in-clinical-trials-of-povorcitinib-100581837","NCT06855498","Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib","A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib","STOP-LTR","Inclusion Criteria:\n\n* Ability to comprehend and willingness to sign a written ICF for the study.\n* Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.\n* Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.\n* Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.\n* Willingness to avoid pregnancy or fathering children as defined in the protocol.\n* Willingness and ability to comply with the study Protocol and procedures.\n\nExclusion Criteria:\n\n* Had been permanently discontinued from study treatment during the parent study.\n* Had temporary study drug interruption due to safety and\u002For efficacy reasons at or after the final visit of the parent study.\n* Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:\n\n  * Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).\n  * Live, attenuated vaccine.\n* Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.\n* Women who are pregnant (or who are considering pregnancy) or breastfeeding.\n* Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and\u002For other products in the same class.\n* Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.\n* Any condition that would, in the investigator's and\u002For sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.\n\nOther protocol-defined Inclusion\u002FExclusion Criteria may apply.","18 Years",{"count":59,"type":22},600,[61],"PHASE3","Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.",[28],[32,65,30,35,31],"povorcitinib",{"date":39,"type":40},{"date":68,"type":40},"2025-02-28",{"date":70,"type":22},"2028-02-28",{"name":46,"class":47},316,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100644021","phase-1-fecal-transplantation-in-hidradenitis-suppurativa--a-pilot-study-100644021","NCT07668713","FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study","FESTIVAL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient with Hurley HS II (moderate severity) or III (very severe)\n* Axillomammary (LC1) or gluteal (LC3) phenotype with at least 4 inflammatory lesions: inflammatory nodule, abscess or active fistula\n* Having presented at least one relapse to a well-conducted medical treatment as proposed by the 2019 French Dermatology Society evidence center recommendations (broad-spectrum antibiotic therapy for 15 to 21 days followed by prophylactic treatment with doxycycline or cotrimoxazole). A relapse is defined as the occurrence of a new attack within 3 months of the introduction of treatment.\n\nExclusion Criteria:\n\n* Allergy or contraindication to amoxicillin-clavulanic acid\n* Patient having received biomedication in the 3 months prior to inclusion\n* Patient suffering from another inflammatory disease (IBD, inflammatory rheumatism, auto-inflammatory disease)\n* Concomitant Clostridioides Difficile infection\n* Immunocompromised patients\n* HIV infection and active HBV\u002FHCV hepatitis\n* No health insurance\n* Pregnant or breast-feeding women\n* Patients already included in a biomedical research study other than an observational study (e.g. registry, cohort)\n* Patients under guardianship\u002Fcuratorship\u002Flegal protection",{"count":81,"type":22},24,[83],"PHASE1","The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge. The pathophysiology of HS, the similarities with Crohn's disease and the data in the literature suggest a role for the digestive flora in HS. The role of the intestinal microbiota has now been clearly demonstrated in the pathophysiology of chronic inflammatory bowel disease (IBD), and is suspected in many other diseases. Fecal microbiota transplantation (FMT) is the gold-standard treatment for recurrent Clostridioides Difficile infection, and is being investigated in a wide range of conditions. Our hypothesis is that FMT would improve inflammatory lesions of HS by modifying patients' digestive microbiota.\n\nTranslated with DeepL.com (free version)",[28,86],"Fecal Microbiota Transplantation (FMT)","NOT_YET_RECRUITING","2026-06-23",{"date":90,"type":40},"2026-06-25",{"date":92,"type":22},"2026-06-01",{"date":94,"type":22},"2031-06",{"name":96,"class":97},"University Hospital, Clermont-Ferrand","OTHER",7,{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":109,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100642252","global-healthcare-study-on-hidradenitis-suppurativa-100642252","NCT07659769","Global Healthcare Study on Hidradenitis Suppurativa","GHSHS","Inclusion Criteria:\n\n* Signed General Consent Form, or equivalent document\n* Confirmed diagnosis of Hidradenitis Suppurativa\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Datasets with ambiguous or unclear diagnosis.","14 Years",{"count":108,"type":22},9600,"5 Years","OBSERVATIONAL","The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.",[28,113],"Hidradenitis Suppurativa (Acne Inversa)",[115,104,116],"Dermastudy","GHRSD","2026-06-15",{"date":119,"type":40},"2026-06-22",{"date":121,"type":40},"2025-01-01",{"date":123,"type":22},"2029-12-31",{"name":125,"class":97},"Julia Tatjana Maul",1,{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":154,"leadSponsor":156,"locationsCount":126},"100630584","phase-4-study-of-efficacy-and-safety-of-secukinumab-in-chinese-adult-patients-with-moderate-to-severe-hidradenitis-suppurativa-100630584","NCT07489573","Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa","An Open-label, Multicenter Study Assessing Efficacy and Safety of Secukinumab up to One Year in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Signed informed consent must be obtained before any assessment is performed.\n* Chinese male and female participants ≥ 18 years of age.\n* Confirmed\u002Fdocumented diagnosis of HS ≥ 6 months prior to baseline.\n* Participants with moderate to severe HS at baseline defined as:\n\n  * A total of at least 5 inflammatory lesions, i.e., abscesses and\u002For inflammatory nodules AND\n  * Inflammatory lesions should affect at least 2 distinct anatomic areas (e.g., left and right axillae)\n\nExclusion Criteria:\n\n* Total fistulae count ≥ 20 at baseline.\n* Any other active skin disease or condition that may interfere with assessment of HS at baseline.\n* Active inflammatory bowel disease.\n* Underlying conditions (including, but not limited to, metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious including tuberculosis and hepatitis, or gastrointestinal conditions), which in the opinion of the investigator, significantly immunocompromise the participant and\u002For place the participant at unacceptable risk for receiving an immunomodulatory therapy.\n* Use or planned use of systemic biological\u002Fnon-biological immunomodulator, corticosteroid treatment for HS, or participation in any interventional trial\n* Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17A, IL-17 A\u002FF or the IL-17 receptor.\n* Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of contraception during the entire study.",{"count":135,"type":22},36,[137],"PHASE4","This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).",[28],[141,142,143,144,145,146,147,148,149],"Moderate to severe hidradenitis suppurativa (HS)","IL-17A","monoclonal antibody","AIN457","secukinumab","HiSCR","pain","efficacy","safety","2026-06-02",{"date":152,"type":40},"2026-06-03",{"date":92,"type":40},{"date":155,"type":22},"2029-11-05",{"name":157,"class":47},"Novartis Pharmaceuticals",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100615057","phase-2-a-study-evaluating-bfb759-in-moderate-to-severe-hidradenitis-suppurativa-100615057","NCT07287644","A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa","A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa","COMPASS 2-HS","Inclusion Criteria:\n\n* Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year.\n* Have moderate to severe disease not well controlled by systemic antibiotic treatment.\n* Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.\n\nExclusion Criteria:\n\n* Have certain infections or other immune conditions.\n* Recently used medications that could interfere with the study.\n* Are pregnant or breastfeeding.","75 Years",{"count":168,"type":22},210,[25,61],"This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.",[28],[30,173],"acne inversa","2026-05-28",{"date":176,"type":40},"2026-05-29",{"date":178,"type":40},"2025-11-03",{"date":180,"type":22},"2027-08-01",{"name":182,"class":47},"Bluefin Biomedicine, Inc.",58,{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":126},"100617251","pelashield-painguard-vs-restrata-in-hs-surgery-100617251","NCT07316192","Pelashield™ PainGuard™ vs Restrata® in HS Surgery","Outcomes With Pelashield™ PainGuard™ Compared to Restrata® in Standard Two-Stage Excision and Closure for Hidradenitis Suppurativa: A Prospective Cohort With Retrospective Comparator","Inclusion Criteria:\n\n* Adults (≥18 years) with a confirmed clinical diagnosis of HS requiring wide surgical excision.\n* Ability to provide informed consent in English.\n* Willingness and ability to attend routine postoperative follow-up visits to monitor healing and readiness for second-stage closure.\n\nExclusion Criteria:\n\n* Non-English-speaking patients (due to consent and follow-up communication limitations).\n* Known allergy or hypersensitivity to wound matrix components (polyvinyl alcohol), local anesthetics, or silver.\n* Known sensitivity to lidocaine or history of cardiac conditions contraindicating lidocaine use (e.g., severe heart block, Adams-Stokes syndrome, Wolff-Parkinson-White syndrome).\n* Pregnancy or active breastfeeding.\n* Severe immunosuppression (e.g., chemotherapy within 3 months, solid organ transplant, uncontrolled HIV with CD4 \\\u003C200, or chronic systemic steroids \\>10 mg prednisone-equivalent\u002Fday).\n* Uncontrolled diabetes (most recent HbA1c \\>10% if available within 3 months).\n* Active systemic infection or sepsis at time of surgery.\n* Inability to complete postoperative follow-up through second-stage closure (e.g., plans to relocate).",{"count":192,"type":22},10,[194],"NA","Hidradenitis Suppurativa (HS) is a long-lasting skin condition that causes painful lumps and infections. In severe cases, patients need surgery to remove the affected skin. After surgery, a wound dressing called a wound matrix is placed over the area to help the skin heal.\n\nThis study will compare two different wound matrices:\n\nRestrata®, which is the current standard treatment. Pelashield™ PainGuard™, a newer dressing that contains silver to reduce bacteria and lidocaine to help with pain.\n\nThe goal of this research is to find out if Pelashield™ PainGuard™ helps patients heal better after surgery than Restrata®. We will look at:\n\nHow quickly healthy granulation tissue (new healing tissue) forms How soon the wound is ready for the second surgery to apply a skin graft How often infections happen after surgery How much narcotic (opioid) pain medication patients need after surgery Patients who receive Pelashield™ PainGuard™ will be enrolled in the study going forward (prospective group). Patients who previously had surgery with Restrata® will be included through a review of their medical records (retrospective group). No additional procedures will be done outside of standard surgical care.",[28],[198,199,200],"Prospective","Wide local Excision","Wound Healing","2026-05-20",{"date":203,"type":40},"2026-05-22",{"date":205,"type":40},"2025-12-01",{"date":207,"type":22},"2026-11",{"name":209,"class":97},"Rutgers, The State University of New Jersey",{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":5},"100592423","phase-2-a-study-with-cit-013-in-hs-patients-100592423","NCT06993233","A Study With CIT-013 in HS Patients","A Phase 2a Double Blind, Randomized, Parallel Arm, Placebo-controlled Trial to Investigate the Effects of Two Dose Levels of CIT-013 on Disease Activity in Patients With Hidradenitis Suppurativa","Citylights","Inclusion Criteria:\n\n* Male or female participants with HS of more than 6 months duration,\n* 18 years of age at screening visit,\n* Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is Hurley Stage II or III (according to Hurley classification system),\n* A total abscess and inflammatory nodule (AN) count of ≥ 5 at screening and Day 1 prior to enrollment\u002Frandomization,\n* Participant must have had an inadequate response to oral antibiotics OR exhibited recurrence after discontinuation to, OR demonstrated intolerance to, OR have a contraindication to oral antibiotics for treatment of their HS,\n* Total draining tunnel count less than 20\n\nExclusion Criteria:\n\n\\- Participants for whom an approved therapy with demonstrated clinical benefit is indicated, available and expected to be tolerated, OR choose to proceed with standard of care treatment options over the IP (after being appropriately informed of the treatment options, risks, and benefits).\n\nAny current and\u002For recurrent clinically significant skin condition in the treatment area other than HS,\n\n* Prior treatment with a recombinant therapeutic protein during the 6 weeks before baseline\n* Prior treatment with any of the following medications before baseline:\n\n  1. Any other systemic therapy for HS (28 days before baseline)\n  2. Any IV anti-infective therapy (14 days before baseline)\n* History of malignancy with exception of non-melanoma skin cancer that has been excised and cured,",{"count":219,"type":22},96,[25],"The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are:\n\nDoes CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS.\n\nParticipants will:\n\nTake receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period",[28],{"date":203,"type":40},{"date":225,"type":40},"2025-10-31",{"date":227,"type":22},"2027-07",{"name":229,"class":47},"Citryll BV",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":239,"briefSummary":240,"conditions":241,"keywords":242,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":256},"100624816","radiotherapy-for-refractory-hidradenitis-suppurativa-100624816","NCT07414550","Radiotherapy for Refractory Hidradenitis Suppurativa","Radiotherapy for Treatment of Recalcitrant Hidradenitis Suppurativa (RADIANT-SUPPoRT)","RADIANTSUPPoRT","Inclusion Criteria:\n\n* Male or female subjects between the age of 18 or older with moderate or severe HS (Hurley Stage II or III) with bilateral axillary disease of approximately equivalent disease severity will be included.\n* Patients on topical and\u002For systemic HS medications for at least 1 month will continue maintenance treatment throughout the study period as per standard of care.\n* Patients willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnancy - Women of childbearing potential must use trial approved birth control and obtain a negative pregnancy test 7 days prior to radiotherapy CT simulation.\n* Severe autoimmune conditions including lupus, scleroderma and mixed connective tissue disease\n* Poorly controlled diabetes per physician discretion, HIV, Hepatitis B\u002FC.\n* Prior therapeutic radiotherapy.\n* Active malignancy.\n* Contraindication to radiotherapy as determined by treating radiation oncologist.\n* Patients who began new systemic treatment for their HS \\\u003C1 month prior to enrollment in trial\n* History of photosensitivity disorders or prior radiation sensitization syndromes\n* Any contraindication to radiotherapy as determined by the treating radiation oncologist.",{"count":192,"type":22},[194],"The goal of this clinical trial is to learn if high-dose radiotherapy can provide sustained disease relief in moderate to severe, treatment resistant Hidradenitis suppurativa patients; could include any of the following: any sex\u002Fgender, and those greater then 18 years old. The main question\\[s\\] it aims to answer are:\n\nOutcome measure 1: Will radiotherapy change the number of inflammatory nodules, abscesses, and draining sinus tracts in the treated axilla compared with the untreated axilla? Outcome measure 2: Will radiotherapy positively change a patient's quality of life, pain levels and symptom burden?\n\nParticipants will receive radiotherapy to one axilla affected by hidradenitis suppurativa. The contralateral axilla will not receive radiotherapy and will continue receiving the standard treatment regimen.\n\nParticipants will...\n\n* Attend a baseline dermatology skin evaluation, complete multiple surveys and an optional participation in a biopsy\n* Attend multiple radiation sessions over 5 weeks\n* Attend 2 follow up visits with dermatology for skin evaluation, complete follow up surveys, and an optional biopsy.",[28],[243,31,244,245,246],"Hidradenitis suppurativa","Radiotherapy","Radiation","Treatment resistant","2026-05-12",{"date":249,"type":40},"2026-05-15",{"date":251,"type":22},"2026-05-01",{"date":253,"type":22},"2028-03-01",{"name":255,"class":97},"Thomas Jefferson University",2,{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":275,"locationsCount":4},"100589902","ndyag-vs-alexandrite-laser-treatment-in-hidradenitis-suppurativa-100589902","NCT06960447","Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa","Comparative Efficacy of Nd:YAG and Alexandrite Laser Treatments in Hidradenitis Suppurativa: A Split-Person, Non-Inferiority Study","Inclusion Criteria:\n\n* Geisinger male or female patients with a diagnosis of hidradenitis suppurativa (all stages of disease)\n* 12-75 years of age\n* Not on concurrent systemic therapy (e.g., antibiotics, biologic therapies)\n* Must have not used systemic therapies within 2 weeks of enrollment in study\n* Able and willing to provide consent\n\nExclusion Criteria:\n\n* Patients who cannot tolerate laser therapy\n* Patients who cannot wear protective eyewear\n* Patients who are pregnant",{"count":265,"type":22},21,[194],"The purpose of this study is to evaluate whether Alexandrite laser treatment is non-inferior to Nd:YAG (neodymium-doped yttrium aluminum garnet) laser treatment of hidradenitis suppurativa (HS).",[28],"2026-04-24",{"date":271,"type":40},"2026-04-28",{"date":273,"type":22},"2026-07",{"date":227,"type":22},{"name":276,"class":97},"Geisinger Clinic",{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":126},"100611740","phase-2-efficacy-and-safety-of-sct650c-in-participants-with-moderate-to-severe-hidradenitis-suppurativa-100611740","NCT07244510","Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa","A Phase II, Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SCT650C in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n1. The participants must be at least 18 years of age at the time of signing the ICF.\n2. Study participants must have a diagnosis of HS based on clinical history and physical examination for at least 6 months prior to the baseline visit; diagnosis must be verifiable through medical notes and documentation.\n3. Study participants must have HS lesions in at least 2 distinct anatomic areas (eg, left and right axilla), 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits.\n4. Study participants must have moderate to severe HS defined as a total of ≥ 5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits.\n5. Study participants must have had a history of inadequate response, intolerance or contraindication to a course of systemic antibiotics for treatment of HS at the Screening Visit as assessed by the investigator.\n6. Participants agree to daily use of topical antiseptics on the areas affected by HS lesions while on study treatment. Allowable antiseptic washes are limited to one of the following: chlorhexidine gluconate, benzoyl peroxide, benzalkonium chloride, benzethonium chloride, or dilute bleach in bath water.\n7. Participants entering the study while undergoing concomitant treatment with systemic antibiotics (as specified in the protocol) must be on a stable dose. A stable dose is defined as a dosage or regimen that has remained unchanged for at least four weeks prior to baseline and is expected to remain unchanged for at least the first 16 weeks of the study.\n8. Female participants must be not of childbearing potential or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy) or, if of childbearing potential (and engaged in sexual activity that could result in procreation), must be willing to use a highly effective method of contraception up to 40 weeks after the last administration of the investigational medical product (IMP) and have a negative pregnancy test prior to the first dose. The following methods are considered highly effective when used consistently and correctly:\n\n   1. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);\n   2. combined (estrogen and progestogen) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal);\n   3. intrauterine device (IUD);\n   4. intrauterine hormone-releasing system (IUS);\n   5. bilateral tubal occlusion;\n   6. vasectomized partner (where postvasectomy testing had demonstrated sperm clearance);\n   7. Sexual abstinence if it is in accordance with a participant's preferred and common lifestyle.\n\n   Note: Participants who use abstinence as a form of birth control must agree to abstain from heterosexual intercourse until 40 weeks after the final dose of IMP. Study personnel must confirm the continued use of abstinence is still in accordance with the participant's lifestyle at regular intervals during the study.\n\n   Male participants with a partner of childbearing potential must be willing to use a condom when sexually active, until 40 weeks after the last administration of IMP.\n9. An Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC) approved written Informed Consent form is signed and dated by the participant.\n\nExclusion Criteria:\n\n1. Study participant has any medical or psychiatric condition could jeopardize or would compromise the study participant's ability to participate in this study as determined by the investigator based on protocol-required assessments.\n2. Study participant has a draining fistula count of \\> 20 at the Baseline Visit.\n3. Study participant has any other active skin disease or condition (eg, bacterial cellulitis, candida intertrigo, extensive condyloma) that may, in the opinion of the investigator, interfere with the assessment of HS.\n4. Study participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease (IBD).\n5. Study participant has a primary immunosuppressive condition, including taking immunosuppressive therapy following an organ transplant or has had a splenectomy.\n6. Female study participant who is breastfeeding, pregnant, or plans to become pregnant during the study or within 40 weeks following the final dose of IMP.\n7. Study participant has an active infection or history of infection(s) as follows:\n\n   * Any infection requiring systemic treatment within 28 days prior to Baseline;\n   * A history of opportunistic, recurrent, or chronic infections that, in the opinion of the investigator, might cause this study to be detrimental to the study participant.\n\n   Opportunistic infections are infections caused by uncommon pathogens (eg, Pneumocystis jirovicii, cryptococcosis), or unusually severe infections caused by common pathogens (eg, cytomegalovirus, herpes zoster).\n8. Study participant has any of the following (for more information, refer to Section 9.2):\n\n   * Known active tuberculosis (TB) disease;\n   * History of active TB involving any organ system unless adequately treated according to World Health Organization\u002F Centers for Disease Control and Prevention therapeutic guidance and proven to be fully recovered upon consult with a TB specialist.\n   * Latent TB infection (LTBI).\n   * High risk of acquiring TB infection.\n   * Current or history of NTMB infection.\n9. Study participant has an acute or chronic hepatitis B virus, hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection or treponema pallidum antibody (TPPA) positive. Study participants who have evidence of, or tested positive for, hepatitis B or hepatitis C will be excluded.\n\n   1. A positive test for hepatitis B virus is defined as: 1) positive for hepatitis B surface antigen (HBsAg+), or 2) HBsAg is negative, HBcAb is positive and HBV-DNA test results ≥ the upper limit of the reference value of each center or need antiviral treatment.\n   2. A positive test for HCV is defined as: 1) positive for hepatitis C antibody (HCVAb+); and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction).\n10. Study participants with concurrent malignancy are excluded. Study participants with a history of malignancy within the past 5 years prior to the Screening Visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been treated and is considered cured.\n11. Study participant has a history of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease.\n12. Study participant has had major surgery within the 3 months prior to the Baseline Visit, or has planned major surgery after entering the study.\n13. Study participant has any systemic disease (ie, cardiovascular, neurological, renal, liver, metabolic, gastrointestinal, hematological, immunological, etc.) considered by the investigator to be uncontrolled, unstable, or likely to progress to a clinically significant degree during the course of the study.\n14. Study participant has had a myocardial infarction or stroke within the 6 months prior to the Screening Visit.\n15. Study participant has a history of chronic alcohol or drug abuse within 6 months prior to Screening as evaluated by the investigator based on medical history and interview.\n16. Study participant has a history of depression and\u002For suicidal thoughts or behaviors are considered not suitable for participation in the clinical study by the investigator.\n17. The participant has a known hypersensitivity to any excipients of SCT650C.\n18. Study participants with prior exposure to biologic agents that block IL-12\u002F23 (e.g., ustekinumab), IL-23 (e.g., risankizumab, guselkumab), or IL-17 (e.g., secukinumab) within 3 months prior to the Baseline visit.\n19. Study participants with prior exposure to anti-TNF therapy (e.g., adalimumab, infliximab) for any indication within 2 months prior to the Baseline visit.\n20. Study participants who have had prior exposure to other immunomodulatory biologic therapies, including anti-IL-1 (e.g., anakinra, canakinumab), within 3 months or 5 half-lives, whichever is longer, prior to the Baseline visit.\n21. Previous treatment with any cell-depleting therapies, including but not limited to anti-CD20 (e.g., rituximab) within 12 months prior to the Baseline visit or until B cell count returns to normal level.\n22. Use of traditional medicines or herbal remedies within 28 days prior to the Baseline visit.\n23. Study participants have received non-allowable topical therapies (including topical antibiotics) for the treatment of HS within 14 days prior to the Baseline visit.\n24. Study participants have received systemic non-biologic therapies (e.g. methotrexate (MTX), cyclosporine A, retinoids, apremilast, phototherapy) for the treatment of HS within 28 days prior to the Baseline visit.\n25. For HS and non-HS related pain, participants have received oral concomitant analgesics (including opioids) within 14 days prior to the Baseline visit.\n\n    Exception: Participants may continue on non-opioid analgesics provided that the dose and dosing regimen have been stable for at least 14 days preceding the Baseline visit and are expected to remain stable at least until Week 16 visit.\n26. Study participants have received any live vaccine within 8 weeks prior to the first dose of study drug (Baseline), or expect the need for live vaccination during study participation including within 40 weeks after the last dose of study drug administration.\n27. Study participants have been treated with any other investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.\n28. Study participant has laboratory abnormalities at Screening, including any of the following:\n\n    * \\>2× the upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)\n    * Total Bilirubin \\>2×ULN\n    * White blood cell count \\\u003C3.00×103\u002FμL\n    * Absolute neutrophil count \\\u003C1.5×103\u002FμL\n    * Lymphocyte count \\\u003C500 cells\u002FμL\n    * Hemoglobin \\\u003C8.5g\u002FdL\n    * Creatinine \\>1.5 ×ULN Note: Tests that result in ALT, AST, ALP or total bilirubin up to 25% above the exclusion limit may be repeated for confirmation during the Screening Period. Upon retesting, participants whose ALT, AST, or ALP remain over the above-defined thresholds should not be randomized.\n29. Study participant has an estimated glomerular filtration rate (GFR) as measured by Chronic Kidney Disease Epidemiology Collaboration \\\u003C60mL\u002Fmin\u002F1.73m2 \\[GFR (male)=(140-age)ⅹWeight\u002Fserum creatinineⅹ1.23; GFR (female)=(140-age)ⅹWeight\u002Fserum creatinineⅹ1.04\\].\n30. Study participant has any other laboratory abnormality that, in the investigator's opinion, will prevent the study participant from completing the study or will interfere with the interpretation of the study results.\n31. The participant is a SinoCellTech (SCT) employee or is an employee of third-party organizations involved in the study.\n32. The participant and\u002For his or her immediate family member is an employee, volunteer, or other worker at the investigative site, either affiliated or not affiliated with this study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.",{"count":285,"type":22},60,[25],"The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Moderate to Severe Hidradenitis Suppurativa",[28],"2026-04-22",{"date":271,"type":40},{"date":292,"type":40},"2025-12-16",{"date":294,"type":22},"2028-02-16",{"name":296,"class":47},"Sinocelltech Ltd.",{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":126},"100635540","phase-4-a-single-center-prospective-self-controlled-observational-real-world-study-of-the-efficacy-and-safety-of-anti-il-17af-monoclonal-antibody-combined-with-non-ablative-dot-laser-for-the-treatment-of-mild-to-moderate-hidradenitis-suppurativa-100635540","NCT07554014","A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A\u002FF Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa","Inclusion Criteria:\n\n1. Patients voluntarily participate in the study and sign the informed consent form.\n2. Male or female participants aged ≥ 18 years (at the time of signing the informed consent form).\n3. Patients with mild to moderate hidradenitis suppurativa: Hurley stage I or II.\n4. Participants have stable disease at screening and baseline, with lesions in ≥ 1 anatomical region and a total abscess and inflammatory nodule (AN) count ≥ 3.\n5. Participants must have intolerance, contraindication, or inadequate response to oral antibiotic treatment for HS for at least 3 months, or have relapsed after stopping such treatment.\n6. Have a basic understanding of the study purpose, the intervention, and possible side effects, and voluntarily sign the informed consent form in accordance with the spirit of the Declaration of Helsinki.\n7. Agree to receive regular treatment, attend follow-up visits, and undergo the required examinations and tests as specified in the clinical study protocol.\n\nExclusion Criteria:\n\n1. Known allergy to the study drug or its excipients.\n2. Prior use of biologics or small molecule targeted agents.\n3. Presence of tunnels on ultrasound at baseline; diagnosed with inflammatory diseases other than HS; history of chronic or recurrent infections; history of malignancy.\n4. History of drug abuse, suicide attempt, or psychiatric disorders.\n5. Participated in another clinical trial within the past 3 months.\n6. Pregnant or breastfeeding women, or those planning to become pregnant during the study period.\n7. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for inclusion.\n8. Systemic use of corticosteroids within the past 4 weeks, or topical use within the past 2 weeks.",{"count":304,"type":22},50,[137],"The goal of this clinical trial is to learn if combining an IL-17A\u002FF monoclonal antibody with non-ablative fractional laser therapy works and is safe in patients with mild to moderate hidradenitis suppurativa (HS). The main questions it aims to answer are:\n\nDoes the combination treatment reduce HS symptoms compared to before treatment? What are the main side effects of this combination treatment? Researchers will compare how participants feel and look after treatment to their own condition before treatment.\n\nParticipants will:\n\nGet the combined treatment once every 4 weeks for 16 weeks Give skin and blood samples before the first treatment and at the last treatment visit Have a final check-up 8 weeks after the last treatment",[28],[309,310],"Laser Therapy","Antibodies, Bispecific","2026-04-21",{"date":271,"type":40},{"date":314,"type":22},"2026-04-01",{"date":316,"type":22},"2027-09-30",{"name":318,"class":97},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":192},"100602402","a-long-term-follow-up-observational-study-to-evaluate-safety-in-subjects-who-have-received-a-gene-modified-regulatory-t-cell-treg-therapeutic-100602402","NCT07123038","A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic","Inclusion Criteria:\n\n* Subject was previously administered at least 1 dose of a Sonoma Biotherapeutics, Inc. gene-modified Treg therapeutic in a prior parent treatment protocol.\n* Subject understands the purpose and risks of the study and is willing to provide written informed consent.\n* Subject is willing to comply with all study procedures for the follow-up period.\n\nExclusion Criteria:\n\n* Participation in the study is not in the subject's best interest, in the opinion of the Investigator","71 Years",{"count":135,"type":22},"To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.",[329,28],"Rheumatoid Arthritis (RA)",[331,332,333,334,30,335,336,337],"Rheumatoid Arthritis","Long Term Follow Up Study","Treg","SBT0000-01","SBT777101","SBT777101-01","SBT777101-02","2026-04-15",{"date":340,"type":40},"2026-04-16",{"date":342,"type":40},"2025-07-22",{"date":344,"type":22},"2040-12",{"name":346,"class":47},"Sonoma Biotherapeutics, Inc.",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":23,"phases":356,"briefSummary":357,"conditions":358,"keywords":359,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":366,"leadSponsor":368,"locationsCount":126},"100613180","phase-2-the-safety-and-efficacy-of-roflumilast-foam-in-hs-100613180","NCT07263230","The Safety and Efficacy of Roflumilast Foam in HS","An Open-label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Hidradenitis Suppurativa","Inclusion Criteria:\n\n1. Male or female subjects aged 18 years or older\n2. Participants are legally competent to sign and give informed consent.\n3. Diagnosis of HS based on clinical history and physical examination for at least 3 months.\n4. Diagnosis of HS (Hurley I or II) with a total AN count of at least 4 to ≤ 10, with no draining tunnels at screening and baseline visits with an AN of \\>4 affecting at least one distinct anatomical region.\n5. Agreement to NOT use topical and systemic antibiotics and intralesional steroids for treatment of HS during the study.\n6. Agreement to NOT use a diluted beach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the study.\n7. Subjects who have had surgery in the treatment area should be at least 3 months post procedure (this applies to deroofing\u002F marsupialization or excision, not incision \\& drainage)\n8. Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening and Baseline\u002FDay 1. In addition, sexually active FOCBP must agree to use at least one form of a highly effective or barrier method of contraception throughout the trial. The use of abstinence as a contraceptive measure is acceptable if this is a consistent part of a lifestyle choice and an acceptable backup method has been identified if the subject becomes sexually active.\n9. Females of non-childbearing potential should be post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization (permanent sterilization methods include hysterectomy, bilateral oophorectomy, hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy).\n10. In good health as judged by the Investigator, based on medical history, targeted physical examination, and vital signs. Subjects and parent(s)\u002Flegal guardian(s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.\n\nExclusion Criteria:\n\n1. Subjects with any medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator\n2. Subjects who cannot discontinue medications and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments (see table of Excluded Medications and Treatments with washout timelines).\n3. Presence of draining tunnels at screening or at baseline visits\n4. Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline\u002FDay 1 and during the study.\n5. Subjects with skin conditions other than HS that would interfere with evaluations of the effect of the study medication on HS, as determined by the Investigator.\n6. Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.\n7. Known allergies to excipients in Roflumilast foam (petrolatum, isopropyl palmitate, methylparaben, propylparaben, diethylene glycol monoethyl ether, hexylene glycol, cetylstearyl alcohol, dicetyl phosphase and ceteth-10 phosphate).\n8. Subjects who cannot discontinue the use of systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously for 2 weeks prior to Baseline\u002FDay 1 and during the study period.\n9. Subjects who have received oral roflumilast (Daxas®, Daliresp®) within 4 weeks prior to Baseline\u002F Day 1.\n10. History of severe depression, suicidal ideation or behavior at Baseline\u002FScreening\n11. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.\n12. Previous treatment with Roflumilast cream or foam (any potency) or current Roflumilast use for any other indication at the baseline visit that would be expected to continue during the trial.\n13. Subjects with a history of major surgery within 4 weeks prior to Baseline\u002FDay 1 or subjects who have major surgery planned during the study.\n14. Subjects with a history of chronic alcohol or drug abuse within 6 months prior to Screening.\n15. Current or a history of cancer within 5 years except for fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.\n16. Parent(s)\u002Flegal guardian(s) who are unable to communicate, read, or understand the local language(s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.\n17. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house.",{"count":355,"type":22},20,[25],"This study investigates the efficacy of topical roflumilast foam in patients with HS.",[28],[31,30,360,361],"Roflumilast","Topical medication","2026-02-09",{"date":364,"type":40},"2026-02-11",{"date":314,"type":22},{"date":367,"type":22},"2028-12",{"name":369,"class":97},"Beth Israel Deaconess Medical Center",{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":384,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":126},"100622809","mait-cells-in-hidradenitis-suppurativa-100622809","NCT07388446","MAIT Cells in Hidradenitis Suppurativa","Role of Mucosal Associated Invariant T Cells in Hidradenitis Suppurativa","HS-MAIT","Inclusion Criteria:\n\n* Subject aged 18 to 65 years (included)\n* Subject able to read, understand and give documented informed consent\n* Subject willing and able to comply with the protocol requirements for the duration of the study\n* Subject with health insurance coverage according to local regulations\n* For woman with childbearing potential, negative pregnancy test at the inclusion visit Specific criteria for HS patients\n* Subject diagnosed with HS for at least 6 months\n* Subject diagnosed with moderate-to-severe HS defined by IHS4 score \\> 4\n* Subject is planned to be treated within 7 days with either adalimumab or secukinumab or bimekizumab under the conditions defined by the French National Health Authority\n* Normal chest imaging within 6 months prior to inclusion.\n* Negative Quantiferon test within 6 months prior to inclusion.\n* Negative HIV, HBV, and HCV serologies within 6 months prior to inclusion.\n* Presence of at least one active inflammatory lesion located outside a strict anatomical fold and outside the face, which will be selected for lesional skin biopsy Specific criteria for control patients\n* Subject diagnosed with plaque psoriasis or back-acne or impetigo\n\nExclusion Criteria:\n\n* \\- Pregnancy or breast-feeding women\n* Subject treated by immunosuppressive\u002Fimmunomodulatory substances including oral corticosteroid or biological agents within 4 weeks before inclusion\n* Subject with any additional condition that, in the opinion of the investigator, may interfere with the assessment or put the subject at risk\n* Linguistic or mentally incapacity to sign the consent form\n* Subject protect by the law (adult under guardianship, or hospitalized in a public or private institution for a reason other than study, or incarcerated)\n* Subject in an exclusion period from a previous study or who is participating in another clinical trial\n* Weight \\\u003C50 kg\n* Diabetes\n* Specific treatments such as metformin or GLP1-agonist that may interfere with MAIT cell activity\n* History of allergic reaction to local anesthetic product\n* History of wound healing disorders (e.g. hypertrophic scars, keloids)\n* Subject treated by oral or topical antibiotics within 2 weeks before inclusion","65 Years",{"count":380,"type":22},45,[194],"Hidradenitis Suppurativa (HS) is a chronic, debilitating inflammatory skin disease characterized by painful, purulent lesions primarily in skin folds. Its pathogenesis remains poorly understood. The clinical benefit observed with both antibiotics and immunosuppressive therapies suggests HS may involve an abnormal immune response to skin microbiota.\n\nMucosal-associated invariant T (MAIT) cells are immune cells that bridge innate and adaptive immunity and are known to regulate microbial flora. Dysfunctional MAIT cells have been implicated in autoimmune diseases such as type 1 diabetes, inflammatory bowel diseases, and psoriasis. Preliminary data from the VERIMMUNE study (NCT05735925) indicate that HS patients show a depletion of circulating MAIT cells and increased infiltration of CD8+ MAIT cells in lesions, associated with reduced activation and greater disease severity. These findings support the hypothesis that MAIT cell dysfunction plays a central role in HS and may serve as a biomarker for treatment response. This exploratory study aims to (Primary) characterize the phenotype and frequency of MAIT cell subsets in the skin and blood of HS patients compared to controls with other inflammatory skin diseases (psoriasis and back-acne); and to determine whether MAIT cell phenotype before treatment predicts clinical response to biologic agents.\n\nThe study will recruit adults (18-65 years) with moderate-to-severe HS and matched controls with plaque psoriasis, or back-acne, or impetigo. All HS participants must be biologic-naïve at baseline and will be treated per national guidelines (adalimumab, secukinumab, or bimekizumab). No therapeutic intervention is imposed; patients are followed according to usual care. Skin and blood samples will be collected before and after treatment to assess immune profiles.\n\nTo minimize bias HS patients will be age\u002Fsex-matched with controls; only patients with active, inflammatory HS lesions will be included; controls were selected to represent related yet distinct pathologies: back-acne (follicular but distinct mechanism), psoriasis (different lesion type, shared type-17 inflammation) and impetigo (skin bacterial infection).\n\nThe Immunophenotyping strategy will use high-dimensional flow cytometry (Cytek® Aurora); researchers will analyze immune cell subsets (e.g., B cells, γδ T cells, NK cells, ILCs, MAIT, NK-T) in skin and blood. Specific markers for activation (CD69, PD-1, ICOS), differentiation (CCR7, CD45RA), proliferation (Ki-67), cytokine receptors, and chemokines will be assessed.\n\nThe primary endpoint will be the frequency of MAIT cells in lesional vs. non-lesional skin and blood compared to controls before and after 12 weeks of biologic agent. The secondary endpoints will be changes in MAIT cell phenotype after 12 weeks of treatment, correlation with clinical improvement (defined by IHS4-55 response: ≥55% reduction in IHS4 score) and MAIT cell functions (assessed in vitro before and after treatment, anti-bacterial activity, capacity to proliferate and to be activated).\n\nThis is a prospective, monocentric, exploratory study with intra-individual comparison and external active controls. The study falls under category 2 (interventional research with minimal risks). Clinical data, biopsy samples, and immune profiles will be collected before and after biologic therapy in moderate-to-severe HS patients (IHS4 ≥4), biologic-naïve, eligible for biologic agents treatment, with no antibiotics or immunosuppressive drugs in the prior month. The controls will be adults with psoriasis or back-acne or impetigo (no follow-up for control patients).\n\nThis study has no direct therapeutic benefit for participants. However, it offers detailed clinical follow-up and may significantly improve understanding of HS pathogenesis. Known procedural risks (local anesthesia, biopsy, venipuncture) are minimal and mitigated through standard precautions and inclusion criteria.\n\nExpected benefits and impact : clarify the role of MAIT cells in HS pathophysiology; identify novel immune biomarkers predictive of biologic therapy response; support future therapeutic stratification and personalized treatment approaches in HS.",[28],[243,385,386,387],"physiopathology","immunology","Mucosal Associated Invariant T cells","2026-01-30",{"date":390,"type":40},"2026-02-05",{"date":392,"type":22},"2026-02-01",{"date":394,"type":22},"2027-02-01",{"name":396,"class":97},"Hospices Civils de Lyon",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":23,"phases":408,"briefSummary":409,"conditions":410,"keywords":411,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":192},"100622542","phase-2-a-study-to-assess-nav-240-in-adult-participants-with-hidradenitis-suppurativa-100622542","NCT07384975","A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa","A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa","Mainsail","Inclusion Criteria:\n\n* History of HS for ≥ 6 months\n* Abscesses and Inflammatory Nodules (lesion) count ≥ 5\n* Inflammatory HS lesions in at least 2 different body regions, one of which must be Hurley Stage II or III\n* Inadequate response to at least one course of antibiotics\n* Topical antiseptics are not required but allowed. If in use, the participant must agree to use one single product consistently through Week 16.\n* Use of oral antibiotics is allowed during the study under the following conditions: the dose and regimen must remain stable until Week 16. Allowed oral antibiotics include doxycycline, minocycline, or tetracycline.\n* Female participants of childbearing potential must have a negative pregnancy test\n* Participants of reproductive potential must use a highly effective method of contraception\n\nExclusion Criteria:\n\n* \\> 20 draining tunnel count\n* Active skin disease (bacterial, fungal, viral infection) that, in the opinion of the Investigator, could interfere with assessment of HS or requires treatment with antibiotic(s) also used to treat HS.\n* Has had major surgery, including HS surgery, within 12 weeks prior to Day 1\n* History of alcohol or drug abuse within the past 2 years.\n* A positive urine drug screen at Screening\n* History or evidence of human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HCV), or a positive test at Screening\n* History or current diagnosis of active tuberculosis (TB), untreated latent TB infection (LTBI), or undergoing current treatment for LTBI, determined by positive TB test\n* History of moderate to severe heart failure or recent (within past 6 months) cerebrovascular accident, myocardial infarction, or coronary stenting.\n* History of immune deficiency","70 Years",{"count":407,"type":22},150,[25],"The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseline (start of the study).\n\nParticipants will:\n\n* Receive NAV-240 dose 1, NAV-240 dose 2 or placebo as a drip into the veins (intravenous infusion).\n* Visit the clinic up to 9 times for checkups and tests over 22 weeks.\n* Complete a daily diary about their skin pain.",[28],[412,31,30,413,414],"NAV-240","Phase 2","Moderate-to-Severe HS","2026-01-26",{"date":417,"type":40},"2026-02-03",{"date":419,"type":40},"2026-01-05",{"date":421,"type":22},"2027-10",{"name":423,"class":47},"Navigator Medicines, Inc.",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":440,"locationsCount":4},"100617798","real-world-study-on-the-burden-of-hidradenitis-suppurativa-100617798","NCT07323303","Real-World Study on the Burden of Hidradenitis Suppurativa","Inclusion Criteria:\n\n1. Patient diagnosed with HS;\n2. Aged ≥18 years;\n3. Able to read and understand French or English;\n4. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1\\. Participation in an interventional study for HS.",{"count":431,"type":22},100,"Despite the significant impact of HS on patients' quality of life (QoL) and daily functioning, there remains limited real-world evidence describing the burden of this condition in Canada. HS is an under-recognized and often misdiagnosed condition, with a substantial psychological and physical burden on patients. Understanding the real-world experiences of individuals living with HS in Canada can help identify unmet needs and inform patient-centered care approaches.",[28],"2025-12-22",{"date":436,"type":40},"2026-01-07",{"date":438,"type":22},"2026-01",{"date":273,"type":22},{"name":441,"class":97},"PeriPharm",{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":450,"enrollmentInfo":451,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":453,"conditions":454,"keywords":455,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":465},"100576475","short-term-treatment-satisfaction-in-hidradenitis-suppurativa-patients-initiated-on-cosentyx-in-routine-clinical-practice-in-saudi-arabia-100576475","NCT06785779","Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia","Survey Assessing Prospective Patient's Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Cosentyx (Secukinumab) in Routine Clinical Practice in Saudi Arabia: ILLUMINATE-SA","ILLUMINATE-SA","Inclusion Criteria:\n\n1. Male or Female adult patients ≥18 years of age at the time of data collection.\n2. Patient with a confirmed diagnosis of active moderate to severe HS.\n3. Secukinumab naive patients (first dose to coincide within one month of the signature of the informed consent) as per locally approved label.\n4. Patients can be using antibiotics or have undergone surgery as per routine clinical practice.\n5. Patients agree to sign an informed consent form (ICF) to be able to complete the questionnaires.\n\nExclusion Criteria:\n\n1. Patients not fulfilling any of the above-mentioned inclusion criteria.\n2. Patient's refusal to be included in the study or refusal to sign the ICF.\n3. A history of off-label indication uses of biological treatment or JAK inhibitor.","99 Years",{"count":452,"type":22},77,"This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment satisfaction as measured by the treatment satisfaction questionnaire for medication (TSQM) at week 24 among moderate to severe HS patients.",[28],[30,31,145,456,457],"NIS","Saudi Arabia",{"date":459,"type":40},"2025-12-30",{"date":461,"type":40},"2025-03-10",{"date":463,"type":22},"2026-09-30",{"name":157,"class":47},4,{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":472,"phases":4,"briefSummary":473,"conditions":474,"keywords":475,"overallStatus":480,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":484,"locationsCount":4},"100484097","managed-access-programs-for-ain457-secukinumab-100484097","NCT05583604","Managed Access Programs for AIN457, Secukinumab","Inclusion Criteria:\n\n* An independent request should be received from a licensed physician (in some instances from Health Authorities, Institutions or Governments).\n* The patient has a serious or life-threatening disease or condition and no comparable or satisfactory alternative therapy is available for diagnosis, monitoring or treatment; patient is not medically eligible for available treatment alternatives or has exhausted all available treatment options.\n* The patient is not eligible or able to enroll in a Novartis clinical trial or continue participation in a Novartis clinical trial.\n* There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.\n* The patient must meet any other medical criteria established by the medical experts responsible for the product or by the Health Authority in a country (as applicable).\n* Provision of the product will not interfere with the initiation, conduct or completion of a Novartis clinical trial or overall development program.","EXPANDED_ACCESS","The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab",[28],[476,477,478,144,145,479],"MAP","Manage Access Program","Hidradenitis suppurativa (HS)","Cosentyx","AVAILABLE","2025-12-10",{"date":483,"type":40},"2025-12-18",{"name":157,"class":47},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":501,"leadSponsor":503,"locationsCount":126},"100613014","phase-4-comparison-of-the-clinical-efficacy-and-safety-of-topical-and-subcutaneous-injection-of-secukinumab-in-hs-100613014","NCT07261072","Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS","Comparison of the Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS: A Prospective Exploratory Trial","Inclusion Criteria:\n\n1. Meet international diagnostic criteria for hidradenitis suppurativa\n2. Aged ≥ 18 years\n3. Disease duration ≥ 6 months and resistance to conventional therapy (no significant improvement for ≥ 3 months)\n4. Lesions were confined to a single anatomical area\n5. Voluntarily signed the informed consent form and was able to cooperate in all visits and examinations.\n\nExclusion Criteria:\n\n1. Hypersensitivity to any component of secukinumab injection\n2. With severe vital organ failure\n3. With active infection or malignancy (malignancy within the past 5 years, except for basal or squamous cell carcinoma of the skin and cured)\n4. Treatment with biologics, immunosuppressants, or systemic corticosteroids within the last 3 months\n5. Pregnant, nursing, or planning conception during the study\n6. Mental disorders or cognitive impairment that precludes understanding of study procedures\n7. Participating in another clinical study and are at risk of an interaction between the study drugs\n8. Other conditions assessed by the investigators as inappropriate for participation in the study",{"count":48,"type":22},[137],"Secukinumab is currently approved in Europe, US and China for the treatment of moderate to severe HS as a biologic agent targeting IL-17A.Two phase III clinical trials (SUNSHINE and SUNRISE) showed that 300 mg s.c. every 2 weeks resulted in 42% to 45% of patients achieving a clinical response (HiSCR) to HS, and the efficacy was sustained through 52 weeks.However, we found in clinical practice that some HS patients present with localized lesions (small areas of involvement, affecting only 1-2 anatomic areas) that are resistant to conventional therapy, and have not yet fulfilled surgical indications, and the need for systemic biologic therapy is controversial.Such patients often experience inadequate response or slow onset of action when they receive secukinumab by routine subcutaneous injection - possibly related to inadequate drug concentration in the focal lesional area and limited local anti-inflammatory effects after systemic administration.In addition, side effects of conventional subcutaneous injection system are greater, and the application is limited in some patients, so it is necessary to explore more appropriate and safer drug delivery method for localized skin lesions.Localized HS, local injection of lesions may enhance anti-inflammatory effects while reducing systemic exposure by increasing drug concentrations at the lesion site.Therefore, exploring novel modes of administration of secukinumab has practical clinical implications based on clinical practice needs and the context of the previous literature.In summary, by exploring the efficacy and safety of local skin injection of secukinumab, this study may provide a new strategy for the treatment of limited HS with sufficient scientific rationale and significant potential benefits and manageable risks.",[28,113,496],"Secukinumab","2025-12-02",{"date":499,"type":40},"2025-12-03",{"date":205,"type":22},{"date":502,"type":22},"2026-12-31",{"name":504,"class":97},"Peking Union Medical College",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":513,"sex":17,"minAge":57,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":517,"conditions":518,"keywords":519,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":126},"100604878","phase-1-1726-nm-laser-for-acne-inversa-hidradenitis-suppurativa-100604878","NCT07155239","1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)","1726-nm Laser (AviClear) for Hidradenitis Suppurativa (HS): A Randomized Split-Body, Sham-Controlled Pilot Trial","WMCREI","Inclusion Criteria:\n\n* Adults 18-60 years; any sex; Fitzpatrick I-VI.\n* Clinical HS, Hurley I-II (Investigator confirmed).\n* At least one inflammatory nodule in a paired, bilateral region (axilla, groin\u002Finguinal, inframammary, inner thigh, or buttock) within 4 weeks prior to baseline.\n* Able to read\u002Fspeak English\u002FChinese\u002FSpanish\u002FVietnamese and sign consent.\n* Willing\u002Fable to comply with visits, pre\u002Fpost-care, standardized photography.\n* Agree to avoid new HS procedures\u002Ftherapies in study areas through Week 24.\n* No laser contraindication; agrees to shave\u002Fclip hair before treatments.\n* Optional translational cohort: willing to undergo 4-mm punch biopsy at baseline and Week 16 from the randomized regions (separate consent).\n\nExclusion Criteria:\n\n* Hurley III (extensive sinus tracts).\n* No qualifying nodule(s) in paired bilateral regions in past 4 weeks.\n* Prior device\u002Fprocedure to target areas within 3 months (chemical peel, dermabrasion, microneedling\u002FRF, other lasers\u002FLBB, cryo\u002Fchemo-destruction)\n* Had Botulinum toxin in target areas within 3 months or planned during study.\n* Had systemic retinoid (e.g., isotretinoin) within 3 months.\n* Photosensitizing meds that, in PI's judgment, materially increase risk and cannot be held.\n* Pregnancy\u002Fbreastfeeding\u002Fplans to conceive during study.\n* Active infection, still healing wounds (investigator judgment) in target areas.\n* History of keloids\u002Fhypertrophic scars, radiation to target areas, malignancy in target areas, diagnosed immunodeficiency, uncontrolled coagulation disorder or therapeutic anticoagulation that cannot be safely managed.\n* Excessive tanning or inability to avoid tanning.\n* Any condition (medical\u002Fmental) or prisoner status that in PI's opinion compromises safety or adherence.",true,"60 Years",{"count":48,"type":22},[83],"Hidradenitis suppurativa (HS) is a long-lasting skin condition that causes painful lumps, abscesses, and tunnels in areas such as the armpits and groin. HS begins around the hair follicle; when the follicle becomes blocked and inflamed, new lesions form. Prior clinical studies of lasers that act on the hair follicle have shown improvement in HS symptoms, and a 1726-nm diode laser-designed to selectively heat oil glands within the follicle-has reduced inflammatory lesions in acne with good tolerability across many skin types.\n\nThis study will test whether a 1726-nm diode laser can safely reduce inflammatory HS lesions in Hurley stage I-II disease. Adults with bilateral (right\u002Fleft) affected areas will be randomized so that one side receives active laser treatment and the other side receives a sham procedure. Participants will have three treatment sessions over 8 weeks and follow-up through Week 24 while continuing their stable HS medications.\n\nThe primary outcome is the percent change in abscess and inflammatory nodule counts on the treated side versus the sham side at Week 16. Secondary outcomes include validated HS responder scores, pain, quality of life, flare rate\u002Fantibiotic use, and safety. Results may support a non-ablative, follicle-directed option for early HS.",[28],[520,521],"hidradenitis suppurative","inversa acne","2025-09-10",{"date":524,"type":40},"2025-09-17",{"date":526,"type":22},"2025-09-15",{"date":502,"type":22},{"name":529,"class":97},"Wynn Medical Center",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":513,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":540,"conditions":541,"keywords":546,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":592,"locationsCount":594},"100594595","skin-disease-profiling-by-an-exploratory-prospective-biomarker-study-in-dermatology-practice-skinergy-100594595","NCT07021495","SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","A Prospective, Multi-Center, Observational Biomarker Real-World Evidence Study for In-Depth Profiling of Patients With Chronic Immune-Mediated Inflammatory Skin Diseases in Daily Practice","SKINERGY","Inclusion Criteria:\n\nPatients:\n\n1. Able to understand and provide a written informed consent prior to any study procedures\n2. Male or non-pregnant female, ≥18 years of age\n3. Patient is willing to refrain from extensively washing (including bathing, swimming) the target lesional skin 12 hours before every study visit day.\n4. Patient is willing and able to comply with the study protocol\n5. Female participants are willing to not get pregnant between M0 until M12, from study entry to the last study visit\n6. The patient is willing to start the prescribed treatment.\n\nDisease-specific inclusion criteria\n\nFor patients with AD:\n\nTo be eligible to participate in this study, a subject must meet all of the following criteria:\n\n6\\. Diagnosis and history of chronic, moderate-to-severe AD (by the Eichenfield revised criteria of Hanifin and Rajka for at least 3 years before baseline visit.\n\n7\\. Documented recent history (last 6 months) of eligibility for (local or systemic) treatment with immunosuppressants, biologics or JAK-inhibitors.\n\n8\\. When applicable, documented recent history (last 6 months) of inadequate response to treatment with topical therapy, immunosuppressants, biologics or JAK-inhibitors.\n\n9\\. Current treatment can include moisturizers, topical treatment and\u002For systemic treatments with preferable wash-out (see exclusion criterion #9). On-study treatment is at physician and patient discretion but must include eligibility to starting new systemic treatment.\n\n10\\. EASI≥7 (moderate-to-severe disease) 11. At least one suitable target lesion at the discretion of the investigator 12. Intention to start treatment with cyclosporine A, dupilumab, tralokinumab, lebrikizumab or a JAK1-inhibitor (abrocitinib or upadacitinib)\n\nFor patients with CLE:\n\nParticipants must have a diagnosis of CLE, including SCLE, CDLE or LET that fulfil the following:\n\n6\\. Confirmed CLE diagnosis by clinicopathological correlation. 7. An overall CLE Disease Area and Severity Index Activity (CLASI-A) Score ≥3 without counting any diffuse alopecia or oral ulcers.\n\n8\\. Intention to start treatment with TCS, hydroxychloroquine or methotrexate (combination or mono-treatment).\n\nIf participating in the exploratory study with the skin biopsy: location of the lesion(s) selected for biopsy preferably outside the facial area (possible are e.g., neck, chest, back, limbs, scalp, ear etc.).\n\nFor patients with CSU:\n\n6\\. Diagnosis of CSU (moderate to severe according to international guidelines (Zuberbier et al, 2022)) for ≥3 months and symptomatic disease despite treatment with second generation H1 antihistamines (up to fourfold the approved dose).\n\n7.Patients currently on an antihistamine (up to fourfold the approved dose) must be on a stable dose for at least 2 weeks prior to day 1 and must maintain the same stable dose throughout the treatment period.\n\n8\\. Intention to start (add-on to antihistamine) treatment of omalizumab, cyclosporine A or BTK inhibitor\\*. (\\*when approved and reimbursed in NL)\n\nFor patients with HS:\n\n6\\. Patient with a history of signs and symptoms consistent with moderate-to-severe HS, based on IHS4 score (Zouboulis et al., 2017), for at least 1 year prior to baseline 7. Current treatment can include topical treatment. On-study treatment is at physician and patient discretion but must include eligibility to starting systemic treatment 8. Intention to start treatment with anti-TNF or anti-IL17 (secukinumab, bimekizumab\\*) \\*when approved and reimbursed in NL.\n\nFor patients with MF:\n\n6\\. A confirmed diagnosis of CTCL MF type and stage classification via histology or clinicopathological correlation 7. For the stage IA-IIA CTCL patients: at least one patch and\u002For one plaque lesion is present 8. Intention to start treatment with topical chlormethine, topical corticosteroids or phototherapy (PUVA \u002F UV-B).\n\nFor patients with PSO:\n\n6\\. Diagnosed with chronic plaque psoriasis at least 6 months prior to study participation 7. PASI≥5 with at least one suitable target lesion at the discretion of the investigator 8. Current treatment can include moisturizers, topical treatment and\u002For systemic treatments with preferable wash-out. On-study treatment is at physician and patient discretion but must include eligibility to starting new systemic treatment 9. Intention to start treatment with biologics: anti-TNF, anti-IL23, anti-IL17 or anti-TYK2\n\nHealthy volunteers:\n\nAll healthy volunteers must meet all of the following inclusion criteria:\n\n1. Signed informed consent before any study-mandated procedure.\n2. Male or non-pregnant female volunteers, ≥18 years of age\n3. Subject is in stable good health as per judgement of the investigator based upon the results of medical history and assessments performed at baseline.\n4. No clinically significant skin disease as judged by the investigator.\n5. No history of hypertrophic scarring or keloid.\n6. Subject is willing to refrain from extensively washing (including bathing, swimming) the skin 12 hours before every study visit.\n7. Subject is willing and able to wash out and withhold any topical treatment (prescription and over-the-counter products) in the investigational area for 2 weeks prior to Day 1.\n8. Subject is willing to refrain from application of any topical product (e.g. ointments, cream, or washing lotions) on the skin 24 hours prior to every study visit day.\n9. Subject is willing and able to wash out any antibiotic therapy for 14 days prior to Day 1.\n10. Subject is willing and able to comply with the study protocol.\n11. Female participants are willing to not get pregnant from study entry to the last study visit\n\nExclusion Criteria:\n\nPatients:\n\n1. Have any other relevant skin infection\u002Fdisease in the treatment area other than the investigated skin disease.\n2. Subjects who have received treatment with any non-marketed drug substance (that is, an agent which has not yet been made available for clinical use following registration) within 4 weeks prior to the baseline visit.\n3. Any other condition, disease, or known factor that could interfere with the study conduct or the study objectives as per judgement of the investigator. 4. Having received treatments for the investigated skin disease within the following intervals prior to the start of the study is not a strict exclusion criterion since this is a real-world study. However, preferred intervals for washout are as follows:\n\n   * 1 week for topical treatment, e.g. corticosteroids, retinoids, vitamin D analogs, calcineurin inhibitors\n   * 4 weeks for phototherapy, e.g. UVB, PUVA, PDT\n   * 4 weeks for non-biologic systemic treatment, e.g. retinoids, methotrexate, cyclosporine, JAK inhibitors\n   * 8 weeks for radiotherapy or surgery in the treatment area\n   * 8 weeks for biologics\n   * 3 months for any systemic chemotherapeutical treatment\n\nDisease specific exclusion criteria for patients with CLE:\n\n5\\. Diagnosed with SLE\n\nDisease specific exclusion criteria for patients with CSU:\n\n5\\. Treatment with omalizumab within 8 weeks prior to Day 1 6. Urticarial or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary, acquired angioedema or drug-induced (e.g., due to C1 esterase inhibitor deficiency, ACE-inhibitor induced).\n\nDisease specific exclusion criteria for patients with MF:\n\n5\\. Ongoing uncontrolled active skin infection, other than secondary impetiginized CTCL lesions as judged by the investigator\n\nDisease specific exclusion criteria for patients with PSO:\n\n5\\. Having primarily erythrodermic, pustular or guttate psoriasis; 6. Having drug-induced psoriasis;\n\nHealthy volunteers:\n\nAll healthy volunteers must meet none of the following exclusion criteria:\n\n1. History of immunological abnormality (e.g. immune suppression, severe allergy, or anaphylaxis) that may interfere with study objectives as per judgement of the investigator.\n2. History or symptoms of any uncontrolled, significant disease including (but not limited to), a neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder that may interfere with the study objectives as per judgement of the investigator.\n3. The use of systemic antibiotic therapy for \\>2 months in the past 12 months.\n4. The use of any immunosuppressive or immunomodulatory therapy within the past 30 days prior to Day 1.\n\n6\\. Loss or donation of blood over 500mL within three months prior to baseline. Participation in an investigational drug study within 3 months prior to baseline visit or more than 4 times a year.\n\n7\\. History of alcohol consumption exceeding 5 standard drinks per day on average within 3 months prior to baseline. Alcohol consumption will be prohibited for at least 24 hours preceding each study visit.\n\n8\\. Positive urine test for drugs or history of abuse at baseline. 9. Exposure to high doses of UV radiation is not permitted within 3 weeks of the first study visit until the end of the study 10. Extreme physical activities are not permitted within 48 hours before each study visit 11. Any other condition, disease, or known factor that could interfere with the study conduct or the study objectives as per judgement of the investigator.",{"count":539,"type":22},840,"The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma subtype mycosis fungoides (MF), chronic spontaneous urticaria (CSU), and cutaneous lupus erythematosus (CLE) in daily practice. Data will be compared with data from healthy volunteers. This study is part of the larger NGID (Next Generation ImmunoDermatology) initiative, of which the main objective is to develop infrastructure that enables personalised patient care. The main questions the SKINERGY study aims to answer are:\n\n* Which biomarkers can discriminate between responders and non-responders to treatment in patients with AD, CLE, CSU, HS, MF, and PSO?\n* How do disease-related biomarkers in patients with AD, CLE, CSU, HS, MF, and PSO differ from those in healthy volunteers?\n* Which (multi-omics) biomarkers are associated with disease subtypes and predict response or non-response to (targeted) therapies in daily clinical practice?\n* How do biomarker profiles compare across different cohorts of patients with immune-mediated inflammatory skin diseases (AD, CLE, CSU, HS, MF, PSO)\n* How do biomarker levels change over time in response to treatment in these patient populations?\n* Which skin tissue biomarkers are associated with disease progression or treatment response?\n* How do the genomic profiles of patients differ across diseases or correlate with treatment outcomes?\n* Can additional imaging biomarkers enhance the characterization of disease profiles or treatment monitoring over time?\n\nResearchers will compare both differences beween patients within a disease group in different treatment arms, as well as patients within the same treatment arm. Additionally, biomarker profiles of patients with different diseases will be evaluated. These comparisons will be made to see if shared or distinct biomarker patterns exist across diseases and treatments, which could inform patient stratification, optimize therapeutic decision-making, and identify potential targets for future interventions.\n\nParticipants will start medication according to national guidelines for the treatment of their inflammatory skin disease (AD: Cyclosporin A, anti-IL4\u002F13, or anti-JAK; PSO: anti-TNF, anti-IL23, ani-IL17, anti-TYK2; HS: anti-TNF, anti-IL17; MF: CHLORM, TSC, PUVA-UV-B; CSU: anti-IgE, Cyclosporin A, anti-BTK\\*; CLE: TSC, HCQ, MTX)\n\n\\*once approved and reimbursed in the Netherlands\n\nParticipants will:\n\n* Take the prescribed medication for their skin disease (in line with standard care in the Netherlands).\n* Visit the clinic for a study visit combined with their standard care appointment 3 times (baseline, month 3, and month 6. An additional 4th visit at month 12 is optional).\n* Fill in an online set of questionnaires from home, 3 times during the study period (an additional 4th time is optional).\n* Patients with CSU fill in the UAS7 (and if applicable the AAS7) daily for the study period.",[542,28,543,544,545],"Chronic Spontaneous Urticaria (CSU)","Psoriasis (PsO)","Atopic Dermatitis (AD)","CTCL\u002F Mycosis Fungoides",[547,548,549,550,551,552,553,554,555,556,34,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585],"Urticaria","Hives","Mast cells","Autoimmune","Autoallergic","Wheals","Angioedema","Abscess","Nodules","Sweat glands","Eczema","Itchy, dry skin","Mycosis Fungoides","Skin patches","Tumors","T-cells","Lupus","Skin rash","Photosensitivity","Plaques","Scaling","Erythema","Induration","Inflammatory skin diseases","Immune-mediated","Deep phenotyping","Multi-omics","Transcriptomics","Lipidomics","Metabolomics","Proteomics","Genomics","Microbiomics","Imaging mass cytometry (CyTOF)","Real-world practice","Standard care","NextGenerationImmunoDermatology","NGID","Biomarkers","2025-08-18",{"date":588,"type":40},"2025-08-19",{"date":590,"type":40},"2025-07-29",{"date":123,"type":22},{"name":593,"class":97},"Leiden University Medical Center",8,{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":603,"conditions":604,"keywords":605,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":613,"locationsCount":126},"100601382","secukinumab-treatment-for-moderate-to-severe-hidradenitis-suppurativa-100601382","NCT07109765","Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa","Real-World Evaluation of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n* age ≥18 years\n* diagnosis of moderate-to-severe HS with Hurley stage II or III\n* Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules\n* inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors\n\nExclusion Criteria:\n\n* active infections (e.g., viral hepatitis, active tuberculosis)\n* use of other biologics or systemic immunosuppressants within the past three months\n* severe organ dysfunction (e.g., hepatic or renal failure)\n* any other conditions that might affect study results",{"count":304,"type":22},"This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.",[28],[30,496,606],"ultrasound","2025-07-31",{"date":609,"type":40},"2025-08-07",{"date":611,"type":40},"2025-06-01",{"date":92,"type":22},{"name":504,"class":97},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":513,"sex":17,"minAge":57,"maxAge":166,"enrollmentInfo":621,"targetDuration":4,"studyType":23,"phases":623,"briefSummary":624,"conditions":625,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":126},"100588840","phase-1-a-phase-i-study-of-qls12010-capsules-safety-tolerability-pk-pd-and-food-effects-in-healthy-adults-and-moderate-to-severe-atopic-dermatitis-patients-100588840","NCT06946641","A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of Single and Multiple Ascending Doses of QLS12010 Capsules in Healthy Adult Participants and Participants With Atopic Dermatitis","Inclusion Criteria for Parts A-C:\n\n* Males and females aged 18-45 (inclusive),\n* Weight: ≥ 50 kg for males and ≥ 45 kg for females, body mass index (BMI): 18.0-30.0 kg\u002Fm2 (inclusive),\n\nInclusion Criteria for Part D:\n\n* Female or male participants between the ages of 18 to 75 years of age.\n* Chronic AD diagnosed by the criteria of Hannifin and Rajka that has been present for at least 6 Months before the Screening Visit.\n* At screening and baseline: EASI score ≥ 16, vIGA-AD™ score ≥ 3, and BSA affected by AD ≥ 10%;\n* The weekly mean score of PP NRS ≥ 4 prior to the first administration (with assessment results for at least 4 days during the week before the first administration \\[D-7 to D-1\\]);\n* As judged by the investigator, within 6 months prior to screening, the patient had an inadequate response to topical medication therapy.\n\nGeneral Exclusion Criteria:\n\n* Participants with diseases that should be excluded as judged by the investigator at screening, including but not limited to the nervous system, psychiatric system, cardiovascular system, blood and lymphatic system, immune system, respiratory system, digestive system, urinary system, metabolic and skeletal system disorders,\n* The 12-lead ECG at screening shows QTcF (QT corrected using Fridericia's formula) \\> 450 ms. If QTcF is \\> 450 ms, the 12-lead ECG should be repeated 2 more times (at least 3 min apart), and the mean of the 3 measurements will be used to determine whether the participant meets the inclusion criteria,\n* Participants who smoke more than 5 cigarettes per day on average within 6 months before screening or are currently using e-cigarettes,\n* Participants who consume more than 14 units of alcohol per week (1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine) within 6 months before screening or have a positive breath alcohol test at screening,\n* Participants who have donated more than 400 mL of blood within 3 months or more than 200 mL of blood within 4 weeks before screening, or plan to donate blood during the study,\n* Participants who have received any strong inhibitor or inducer of CYP3A4 within 4 weeks before screening,\n* Participants who have received any prescription drugs, OTC drugs, traditional medicines, and dietary supplements within 2 weeks before the first dose or 5 half-lives (whichever is longer).\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":622,"type":22},102,[83],"The goal of this clinical trial is to evaluate the safety, tolerability, PK, and PD of single and multiple ascending doses of QLS12010 Capsules and the effect of food on their PK profiles in healthy adult participants and participants with atopic dermatitis. This study consists of four parts: Part A is a single ascending dose (SAD) study, once sufficient safety and PK data are obtained from the SAD cohorts, the SMC will determine the dosage of initial cohort in Part B, which consists of three multiple ascending doses (MAD) cohorts of QLS12010 Capsules. Part C is a randomized, open-label, two-cycle, crossover food effect study under fasting and fed (high-fat meal) conditions. Part D is to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics, and preliminary efficacy of QLS12010 Capsules following multiple oral administrations in adult participants with atopic dermatitis (AD).",[626,28,329],"Atopic Dermatitis","2025-07-28",{"date":607,"type":40},{"date":630,"type":40},"2025-03-31",{"date":632,"type":22},"2026-04",{"name":634,"class":47},"Shanghai Qilu Pharmaceutical Research and Development Center LTD",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":23,"phases":645,"briefSummary":646,"conditions":647,"keywords":648,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":126},"100598100","phase-1-neutralizing-interferon-type-1-in-hidradenitis-suppurativa-100598100","NCT07067099","Neutralizing Interferon Type 1 in Hidradenitis Suppurativa","Use of Plasma With Neutralizing Autoantibodies to Type I Interferons in Patients With Severe Refractory Flare-up of Hidradenitis Suppurativa","NIHS-I","Inclusion Criteria:\n\n* Men and women aged over 18\n* Patients with Hidradenitis suppurativa (Hurley stages II-III)\n* Disease affecting at least two distinct anatomical areas,\n* Total count of abscesses (A) and inflammatory nodules (N) ≥ 3\n* IHS4 score ≥ 11\n* Treatment of pain with opioids (≥ 20 mg\u002Fday)\n* Resistance to previous use (for at least 3 months) of systemic antibiotics and TNF inhibitors (infliximab or adalimumab) or anti-IL17 (secukinumab).\n* Vaccinations against SARS-CoV-2 and influenza up to date (or able to be carried out prior to the study procedure)\n* Women using an effective method of contraception\n* Signed informed consent\n\nExclusion Criteria:\n\n* Active viral infection: herpes, VZV, HIV, HBV, HCV\n* Active bacterial infection requiring systemic antibiotics\n* Known allergy to blood components\u002Fplasma proteins\n* Poor myocardial function (increased risk of for transfusion-associated circulatory overload) (symptomatic left ventricular failure and ejection fraction \\\u003C 40%)\n* Pregnant women\n* Subjects with no social security coverage",{"count":644,"type":22},6,[83],"The purpose of the study is to evaluate the safety and type 1 Interferon (IFN) neutralization in patients with refractory severe Hidradenitis Suppurativa (Hurley stage III) after transfusion of plasma containing high titer anti-IFN-1 autoantibodies.",[28],[649,650],"Plasma therapy","Neutralizing type-1 interferon autoantibodies","2025-07-04",{"date":653,"type":40},"2025-07-16",{"date":655,"type":22},"2025-09",{"date":657,"type":22},"2026-09",{"name":659,"class":97},"Centre Hospitalier Universitaire de Besancon"]